Markets:

Overview

News

Currencies

International

Treasuries

Geron Corporation - Common Stock (NQ:GERN)

0.9518 -0.1282 (-11.87%)

Delayed Quote Updated: 3:37 PM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points ↗

January 04, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.

Via Benzinga

Geron Stock Surges After Encouraging Data From Rare Blood Cancer Trial ↗

January 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 04, 2023

Via Benzinga

Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket ↗

January 04, 2023

Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares rose 63.2% to $0.4201 in pre-market trading after dropping 8% on Tuesday. Elys Game Technology and Cloakbook were recently granted a license to...

Via Benzinga

Geron (GERN) Q3 2022 Earnings Call Transcript ↗

November 04, 2022

GERN earnings call for the period ending September 30, 2022.

Via The Motley Fool

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 04, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

January 04, 2023

From Geron Corporation

Via Business Wire

Geron Announces Conference Call for Top-Line Results from IMerge Phase 3

January 03, 2023

From Geron Corporation

Via Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 22, 2022

From Geron Corporation

Via Business Wire

Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

December 12, 2022

From Geron Corporation

Via Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 17, 2022

From Geron Corporation

Via Business Wire

Geron to Participate in Stifel 2022 Healthcare Conference

November 07, 2022

From Geron Corporation

Via Business Wire

Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

November 03, 2022

From Geron Corporation

Via Business Wire

Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

November 03, 2022

From Geron Corporation

Via Business Wire

Earnings Preview: Geron ↗

November 02, 2022

Geron (NASDAQ:GERN) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Geron will report an...

Via Benzinga

10 Best Medical Stocks Under $5 ↗

October 29, 2022

The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022 ↗

October 28, 2022

Upgrades

Via Benzinga

Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

October 27, 2022

From Geron Corporation

Via Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 20, 2022

From Geron Corporation

Via Business Wire

Marathon Digital, Coinbase Global And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

September 27, 2022

U.S. stock futures traded higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market trading session.

Via Benzinga

Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket ↗

September 27, 2022

Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for...

Via Benzinga

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2022

From Geron Corporation

Via Business Wire

H.B. Fuller, Lennar And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

September 22, 2022

U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving higher in today’s pre-market trading session.

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q4 ↗

September 15, 2022

A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

September 13, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

September 08, 2022

From Geron Corporation

Via Business Wire

Geron's Return On Capital Employed Insights ↗

September 06, 2022

According to data from Benzinga Pro, during Q2, Geron's (NASDAQ:GERN) reported sales totaled $73 thousand. Despite a 6.58% increase in earnings, the company posted a loss of $28.12 million.

Via Benzinga

Geron to Present at Upcoming Investor Conferences

September 01, 2022

From Geron Corporation

Via Business Wire

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 22, 2022

Via Benzinga

Geron Commences Initial-Stage Rare Blood Cancer Combination Study ↗

August 22, 2022

Geron Corporation (NASDAQ: GERN) has dosed first patient in IMproveMF study evaluating imetelstat in combination with ruxolitinib for patients with frontline myelofibrosis (MF).

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.